WHO has recommended a complete ban on the treatment of COVID-19 with ivermectin and VV116. The organization attributes this to the presence of side effects of drugs, as well as the low quality of data obtained during the VV116 trials.
Experts from the World Health Organization have proposed banning the use of ivermectin and the antiviral drug VV116, developed at the beginning of the pandemic by the Shanghai Institute of Medicines, for the treatment of any form of COVID-19. The updated recommendations have been published in the BMJ.
Clinical trials have shown that ivermectin and VV116 should not be used to treat mild to severe forms of COVID-19, study says. The WHO attributes this both to the presence of side effects from ivermectin and to the fact that the quality of the data obtained during the VV116 trials turned out to be low. Because of this, it is not possible to evaluate the effect of taking the drug.
The antiparasitic drug ivermectin has attracted interest due to reports of its ability to suppress the replication of coronavirus. However, such a statement was not confirmed. In March 2021, WHO issued recommendations not to use ivermectin outside of clinical trials. Further experiments showed the presence of side effects of the drug. WHO experts made a similar recommendation regarding VV116.
WHO experts have also developed a set of criteria that will help divide patients with mild forms of COVID-19 into three groups: with low, medium and high risks of hospitalization. This will reduce the risk of infection, increase patient survival and improve the availability of drugs, the study notes.